Enrique Grande, MD, on the Final Analysis of IMvigor130: Atezolizumab-Based Treatment of Metastatic Urothelial Carcinoma

Posted: Sunday, June 4, 2023

Enrique Grande, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical implications of the final analysis of data from the IMvigor130 trial, which focused on the use of atezolizumab plus a platinum and gemcitabine in patients with metastatic urothelial carcinoma. She also explores the differences between the chemotherapy agents used (carboplatin and cisplatin) in this patient population.